查詢結果分析
相關文獻
- 心臟保護藥於心肌梗塞病人之評估
- 心肌梗塞病患住院期間發生不確定感內容及其相關因素之探討
- 心肌梗塞病人之性功能障礙與護理
- 運動後低血壓反應與血壓控制之探討
- 急性心肌梗塞住院病人的不確定感與因應行為之探討
- 急性心肌梗塞症
- Myocardial Contrast Echocardiography and Dobutamine Echocardiography in Predicting Viable Myocardium
- Safety and Efficacy of Primary Percutaneous Transluminal Coronary Angioplasty for Acute Myocardial Infarction Complicated by prolonged Cardiopulmonary Resuscitation
- 心肌梗塞病患之性探討
- Troponin T/I及其臨床意義
頁籤選單縮合
題 名 | 心臟保護藥於心肌梗塞病人之評估=The Evaluation of Cardioprotective Medications in Myocardial Infarction Patients |
---|---|
作 者 | 邱春吉; 戴慶玲; 王郁青; | 書刊名 | 藥學雜誌 |
卷 期 | 32:1=126 2016.03[民105.03] |
頁 次 | 頁18-24 |
分類號 | 418.22 |
關鍵詞 | 心臟保護藥; 心肌梗塞; Cardioprotective medications; Myocardial infarction; Beta-blocker; ACEI/ARB; |
語 文 | 中文(Chinese) |
中文摘要 | 在台灣心血管疾病是第二常見的死亡原因,雖然治療指引推薦多種心臟保護藥 使用於心肌梗塞的預防,但次級預防的藥物治療仍然不理想。本研究目的是評估四 類心臟保護藥於心肌梗塞後門診病人之使用率。本研究從2012/01/01至2014/12/31 於南臺灣某醫學中心執行,研究相關數據與資料以 SPSS 16.0版統計軟體處理和分 析。總共有208位病人完成研究,研究前個別藥物的利用率 antiplatelet (intervention group: IG 100% vs control group:CG 100%)、beta-blocker (IG 82% vs CG 82%)、ACEI/ ARB (angiotensin converting enzyme inhibitor/angiotensin receptor blocker)(IG 88% vs CG 87%)、statin (IG 87% vs CG 82%)。研究後個別藥物的利用率 antiplatelet (IG 96% vs CG 99%)、beta-blocker (IG 81% vs CG 78%)、statin (IG 89% vs CG 80%) 等仍高,但 ACEI/ARB 的利用率明顯下降 (IG 72% vs CG 75%)。四類心臟保護藥併用率於兩組研 究前到後皆偏低 (IG 63% to 57%, p = 0.19 vs CG 63% to 51%, p = 0.04),對於心肌梗塞 後門診病人給予實證之最佳次級預防心血管藥物治療,仍具有極大的改善空間。 |
英文摘要 | Cardiovascular (CV) disease is the second most common cause of mortality in Taiwan. Although guidelines recommend multiple cardioprotective medications to prevent myocardial infarction (MI), but the use of secondary prevention pharmacotherapy after MI remains suboptimal. The aims of this study is to determine the utilization rates of the four types of cardioprotective medications in post-MI outpatients. This study was conducted from January 1, 2012 to December 31, 2014 in a medical center in Taiwan. All data processing and analyses were carried out using the SPSS 16.0 for windows. A total 208 patients completed the study. At baseline, the individual utilization rate for antiplatelet (intervention group: IG 100% vs control group:CG 100%), beta-blocker (IG 82% vs CG 82%), statin (IG 87% vs CG 82%) and ACEI/ ARB (angiotensin converting enzyme inhibitor/angiotensin receptor blocker) (IG 88% vs CG 87%). End of study, the induvidual utilization rate was still high for antiplatelet (IG 96% vs CG 99%), beta-blocker (IG 81% vs CG 78%) and statin (IG 89% vs CG 80%), but decreased in the ACEI/ARB (IG 72% vs CG 75%). The utilization rate was low for all four classes of cardioprotective medications from baseline to final data within both groups in this study (IG 63% to 57%, p = 0.19 vs CG 63% to 51%, p = 0.04) , there is still a large room for improvement and optimization of the evidence-based secondary prevention cardiovascular pharmacotherapy in post- MI outpatients. |
本系統中英文摘要資訊取自各篇刊載內容。